BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34362509)

  • 1. [Distribution of ETV6-ABL Fusion Gene in Hematopoietic Cell Populations of Myeloproliferative Neoplasm].
    Chen Y; Liu Q; Li Y; Wei H; Rao Q; Wang M; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1242-1246. PubMed ID: 34362509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of BCR/ABL fusion gene by fluorescence in situ hybridization and its clinical application].
    Zhou RL; Mo YX; Lan M; Lin JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1283-8. PubMed ID: 22040989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
    Xie W; Wang SA; Hu S; Xu J; Medeiros LJ; Tang G
    Cancer Genet; 2018 Dec; 228-229():41-46. PubMed ID: 30553471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion.
    Andreasson P; Johansson B; Carlsson M; Jarlsfelt I; Fioretos T; Mitelman F; Höglund M
    Genes Chromosomes Cancer; 1997 Nov; 20(3):299-304. PubMed ID: 9365838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
    Horváth A; Baghiu MD; Pap Z; Bănescu C; Mărginean CO; Pávai Z
    Rom J Morphol Embryol; 2011; 52(3):907-13. PubMed ID: 21892537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
    Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
    Million RP; Aster J; Gilliland DG; Van Etten RA
    Blood; 2002 Jun; 99(12):4568-77. PubMed ID: 12036890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of bcr/abl fusion gene changes in patients with chronic myeloid leukemia after allo-HSCT by real-time quantitative reverse transcription polymerase chain reaction and its significance].
    Xue M; Wang HX; Duan LN; Yan HM; Zhu L; Liu J; Ding L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1350-3. PubMed ID: 19099642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
    Tbakhi A; Pettay J; Sreenan JJ; Abdel-Razeq H; Kalaycio M; Hoeltge G; Miller ML; Tubbs RR
    Am J Clin Pathol; 1998 Jan; 109(1):16-23. PubMed ID: 9426513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
    Gross AW; Zhang X; Ren R
    Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
    Hao SX; Ren R
    Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
    Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare cause of persistent leukocytosis with massive splenomegaly: Myeloid neoplasm with BCR-PDGFRA rearrangement-Case report and literature review.
    Gao L; Xu Y; Weng LC; Tian ZG
    Medicine (Baltimore); 2022 Jun; 101(24):e29179. PubMed ID: 35713428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.